Monalizumab
Monalizumab
Monalizumab (pronunciation: mo-na-li-zu-mab) is a type of immunotherapy drug used in the treatment of certain types of cancer. It is a monoclonal antibody that targets the NKG2A receptor on Natural Killer cells and T cells, enhancing the body's immune response against cancer cells.
Etymology
The name "Monalizumab" is derived from the term "monoclonal antibody". The prefix "Mono-" refers to the single type of immune cell that the drug targets, while "-lizumab" is a common suffix used in the naming of monoclonal antibodies.
Mechanism of Action
Monalizumab works by blocking the NKG2A receptor on Natural Killer cells and T cells. This receptor normally inhibits the immune response, so by blocking it, Monalizumab enhances the body's ability to attack cancer cells.
Clinical Trials
Monalizumab has been tested in several clinical trials for its effectiveness in treating various types of cancer, including head and neck cancer, colorectal cancer, and ovarian cancer. The results of these trials have shown promise, but further research is needed to fully understand the drug's potential.
Side Effects
Like all drugs, Monalizumab can cause side effects. These may include fatigue, nausea, diarrhea, and skin rash. Patients should discuss potential side effects with their healthcare provider before starting treatment.
Related Terms
External links
- Medical encyclopedia article on Monalizumab
- Wikipedia's article - Monalizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski